Cargando…

Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2

Fibrotic disease is a significant cause of mortality. CCN2 (connective tissue growth factor [CTGF]), a member of the CCN family of matricellular proteins, plays a significant role in driving the fibrogenic effects of cytokines such as transforming growth factor β (TGFβ). It has been proposed that ot...

Descripción completa

Detalles Bibliográficos
Autor principal: Leask, Andrew
Formato: Texto
Lenguaje:English
Publicado: Springer Netherlands 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721085/
https://www.ncbi.nlm.nih.gov/pubmed/19475498
http://dx.doi.org/10.1007/s12079-009-0056-4
_version_ 1782170169266667520
author Leask, Andrew
author_facet Leask, Andrew
author_sort Leask, Andrew
collection PubMed
description Fibrotic disease is a significant cause of mortality. CCN2 (connective tissue growth factor [CTGF]), a member of the CCN family of matricellular proteins, plays a significant role in driving the fibrogenic effects of cytokines such as transforming growth factor β (TGFβ). It has been proposed that other members of the CCN family can either promote or antagonize the action of CCN2, depending on the context. A recent elegant study published by Bruce Riser and colleagues (Am J Pathol. 174:1725–34, 2009) illustrates that CCN3 (nov) antagonizes the fibrogenic effects of CCN2. This paper, the subject of this commentary, raises the intriguing possibility that CCN3 may be used as a novel anti-fibrotic therapy.
format Text
id pubmed-2721085
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-27210852009-08-06 Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2 Leask, Andrew J Cell Commun Signal Bits and Bytes Fibrotic disease is a significant cause of mortality. CCN2 (connective tissue growth factor [CTGF]), a member of the CCN family of matricellular proteins, plays a significant role in driving the fibrogenic effects of cytokines such as transforming growth factor β (TGFβ). It has been proposed that other members of the CCN family can either promote or antagonize the action of CCN2, depending on the context. A recent elegant study published by Bruce Riser and colleagues (Am J Pathol. 174:1725–34, 2009) illustrates that CCN3 (nov) antagonizes the fibrogenic effects of CCN2. This paper, the subject of this commentary, raises the intriguing possibility that CCN3 may be used as a novel anti-fibrotic therapy. Springer Netherlands 2009-05-29 2009-06 /pmc/articles/PMC2721085/ /pubmed/19475498 http://dx.doi.org/10.1007/s12079-009-0056-4 Text en © The Author(s) 2009
spellingShingle Bits and Bytes
Leask, Andrew
Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2
title Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2
title_full Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2
title_fullStr Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2
title_full_unstemmed Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2
title_short Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2
title_sort yin and yang: ccn3 inhibits the pro-fibrotic effects of ccn2
topic Bits and Bytes
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721085/
https://www.ncbi.nlm.nih.gov/pubmed/19475498
http://dx.doi.org/10.1007/s12079-009-0056-4
work_keys_str_mv AT leaskandrew yinandyangccn3inhibitstheprofibroticeffectsofccn2